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Abstract
The contamination of adenovirus (Ad) stocks with adeno-associated viruses (AAV) is usually unnoticed, and it
has been associated with lower Ad yields upon large-scale production. During Ad propagation, AAV con-
tamination needs to be detected routinely by polymerase chain reaction without symptomatic suspicion. In this
study, we describe that the coinfection of either Ad wild type 5 or oncolytic Ad with AAV results in a large-
plaque phenotype associated with an accelerated release of Ad from coinfected cells. This accelerated release was
accompanied with the expected decrease in Ad yields in two out of three cell lines tested. Despite this lower Ad
yield, coinfection with AAV accelerated cell death and enhanced the cytotoxicity mediated by Ad propagation.
Intratumoral coinjection of Ad and AAV in two xenograft tumor models improved antitumor activity and
mouse survival. Therefore, we conclude that accidental or intentional AAV coinfection has important implica-
tions for Ad-mediated virotherapy.
Introduction
Oncolytic viruses offer a unique opportunity to treatcancer because selective replication in tumor cells mul-
tiplies the amount of cells that become infected, a major lim-
itation in cancer gene therapy. Among different viruses,
adenovirus (Ad) has been extensively modified to achieve
tumor selective replication (Alemany, 2007). However, de-
spite promising preclinical results, limited efficacy in over 20
clinical trials suggests that Ad oncolytic potency needs to be
improved (Russell et al., 2012). A potent oncolytic Ad should
efficiently release its progeny to facilitate rapid spread
through the tumor. Despite that Ad release is key for efficient
oncolysis (Gros, 2010), it is slow, as it occurs late in the virus
life cycle when the adenovirus death protein (ADP) has ac-
cumulated (Tollefson et al., 1996b). Moreover, Ad release is
inefficient, as less than 20% of the total virus produced is
released within 2 days postinfection. Mathematical models
that combine parameters of Ad replication rate, tumor growth
rate, and immune response point to virus release as a key
factor for efficacy (Wein et al., 2003). Ads with deleted
E1B19K, truncated i-leader protein, or overexpressing ADP
show faster progeny release and higher oncolytic activity
(Sauthoff et al., 2000; Ramachandra et al., 2001; Doronin et al.,
2003; Puig-Saus et al., 2012), highlighting Ad release as a key
parameter for intratumor spread and antitumor efficacy.
Adeno-associated viruses (AAVs) were first described in
1965 as nonautonomous viruses contaminating Ad stocks.
AAVs are nonpathogenic defective parvoviruses. The name
‘‘AAV’’ reflects the inability to efficiently replicate in the
absence of a helper virus, such as Ad, human papilomavirus
or herpes simplex virus. Several AAV serotypes have been
described (Gao et al., 2004; Schmidt et al., 2006) with different
tissue tropism (Grimm et al., 2003; Muller et al., 2006). Studies
on AAV-Ad interaction frequently involve AAV2 and Ad
wild type 2 (Ad 2) or Ad wild type 5 (Ad5). AAV2-Ad co-
infection leads to lower levels of Ad gene and protein ex-
pression in an AAV dose-dependent manner, affecting
certain Ad transcripts and proteins more than others (Timpe
et al., 2006). AAV contamination has been associated with
lower Ad yields (burst size) (Hoggan et al., 1966; Carter et al.,
1979). However, the effect of AAV contamination on Ad
cytotoxicity is unclear, with a lower cytotoxicity described in
HeLa cells ( Jing et al., 2001) and an enhanced cytolysis and
apoptosis in A549 cells (Timpe et al., 2007).
Considering the previously described effects of AAV on
Ad yield and cytotoxicity and the current interest on viro-
therapy with Ads, we studied the effect of AAV on Ad
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release, cytotoxicity, and oncolytic potency. Ad formed large
plaques when combined with either AAV2 or AAV6, a
phenotype caused by a faster and more efficient Ad release
from infected cells. Of note, AAV also enhanced cell death
and improved therapeutic activity of an oncolytic Ad,
opening the possibility to use AAV in Ad-mediated viro-
therapy.
Materials and Methods
Cell lines and viruses
HEK293 and A549 cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). NP9 cells
were established in our laboratory (Villanueva et al., 1998).
All cell lines were routinely tested for mycoplasma and were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 5% fetal bovine serum (FBS), penicillin
(50 mg/ml), and streptomycin (50 mg/ml) at 37C and 5%
CO2. Human Ad5 was obtained from ATCC. Oncolytic Ad
ICOVIR15 is described elsewhere (Rojas et al., 2010). AAV
serotype 2 was generated by transfection of HEK293 mono-
layers with psub201 and a plasmid supplying helper genes
as previously described (Casper et al., 2005). AAV serotype 6
was generated by pAAV6 (kindly provided by Dr. David W.
Russell, Department of Medicine, University of Washington,
Seattle, WA) and helper plasmid transfection of HEK293.
AAV6 was purified over iodixanol gradient as described
(Zolotukhin et al., 1999). AAVs were tittered by quantitative
polymerase chain reaction.
Cell-plaque assay
A549 monolayers were infected with Ad5 or ICOVIR15 at
a multiplicity of infection (MOI) of 50, or coinfected with
either Ad5 or ICOVIR15 (50 MOI) plus either AAV2 or
AAV6 at 1,000 viral particles (vp)/cell. Four hours postin-
fection, cells were washed with phosphate buffered saline
(PBS) and trypsinized. About 20 ll of each cell suspension
was diluted 1/5 in trypan blue, and cells were counted in a
Neubauer chamber. Fifty cells of each infection condition
were added on top of near-confluent A549 monolayers see-
ded in six-well plates. After 4 hr, the medium was removed
and cells were covered with a 1:1 mix of DMEM–5% FBS:1%
agarose. Once agarose solidified, DMEM–5% FBS was ad-
ded. To better visualize plaques, monolayers from the dif-
ferent infection conditions were stained by incubation with
0.5 mg/ml thiazolyl blue tetrazolium bromide (MTT; Sigma-
Aldrich, St. Louis, MO) at 37C and 5% CO2 for 4 hr.
Virus release and production assays
HEK293, A549, and NP9 monolayers seeded in 24-well
plates were infected in triplicate at an Ad MOI that allowed
100% infectivity (5 for HEK293; 50 for A549 and NP9 cells)
and at different vp/cell of AAV6 depending on the cell line
(100 for HEK293; 100, 1,000, 10,000, and 100,000 for A549;
and 1,000 for NP9). Four hours after infection, cultures were
washed thrice with PBS and incubated in a fresh virus-free
medium. At the indicated time points after infection (time 0
meaning immediately after addition of the fresh medium), a
small fraction of the supernatant (SN) was collected, and the
cells and the medium were harvested and frozen-thawed
three times to obtain the cell extract (CE). Viral titers were
determined by an antihexon staining-based method (Cas-
callo et al., 2007). A two-tailed Student’s t-test was used to
study statistical significance.
Cytotoxicity assays
A549 monolayers seeded in six-well plates were mock-
infected or infected with ICOVIR15 (50 MOI) alone or com-
bined with AAV6 at 1,000 vp/cell. Four hours postinfection,
cells were washed thrice with PBS and incubated with fresh
virus-free DMEM–5% FBS at 37C and 5% CO2. At the in-
dicated time points, samples were collected and analyzed
for lactate dehydrogenase (LDH) levels (expressed in uKAt/
liter) in the Biochemistry Service of the Bellvitge Hospital
following the protocol established by the International Fed-
eration of Clinical Chemistry. The absorbances at 340 and
700 nm were determined for each sample on a Cobas c711
(Roche Diagnostics, Basel, Switzerland) spectrophotometer,
calibrated with a c.f.a.s. (Roche Diagnostics, ref. 759350) us-
ing reagent LDH 1 Gen. 2 (Roche Diagnostics, ref. 04964560
022). The significance of differences between groups was
assessed by a two-tailed Student’s unpaired t-test. For the
trypan blue exclusion assay, SNs were removed at the indi-
cated time points. Cells were trypsinized and combined with
SNs. Cell and SN mixture was diluted 1/10 in trypan blue,
and cells were counted in a Neubauer chamber. Cells were
counted in groups of 100 (500–600 cells for each time point
and condition). Statistical significance between groups was
assessed by a two-tailed Student’s unpaired t-test. For cell
morphology, unfixed cells were microscopically examined
and photographed at the indicated time points postinfection
with a Leica DMIL LED light microscope and Leica Appli-
cation Suite LAS v.2.6 software (Leica, Wetzar, Germany).
In vitro propagation assays
Propagation assays were performed by seeding 30,000
A549 or NP9 cells per well in 96-well plates in DMEM–5%
FBS. Cells were infected by triplicate with serial dilutions of
ICOVIR15 alone, starting with 200 transducing units (TU)/
cell, or coinfected with four AAV6 doses, starting with 400,
4,000, 40,000, or 400,000 vp/cell for A549 or NP9 cells. These
doses were chosen to match the number of functional AAV
and Ad particles considering an Ad dose of 200 MOI and a
similar TU/vp ratio for both viruses; thus, we used 4,000 vp
of AAV. We used one lower dose and two higher doses in
order to demonstrate a dose-dependent effect of AAV on Ad
propagation-mediated citotoxicity. At day 5 postinfection for
A549 cells and day 6 postinfection for NP9 cells, plates were
washed with PBS and stained for total protein content (bi-
cinchoninic acid assay; Pierce Biotechnology, Rockford, IL).
Absorbance was quantified and the TU per cell required to
produce 50% of culture growth inhibition (IC50 value) was
estimated from dose–response curves by standard nonlinear
regression (GraFit; Erithacus Software, Horley, United
Kingdom), using an adapted Hill equation. A two-tailed
Student’s t-test was used to study the statistical differences
between the IC50 values of different groups. For assays using
coinfected cells, monolayers of A549 or NP9 cells were in-
fected with ICOVIR15 alone (50 MOI) or combined with
1,000 vp/cell of AAV6. Four hours postinfection, cells were
washed once with PBS, trypsinized, and counted in a Neu-
bauer chamber. Serial dilutions of infected cells, starting with
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1,000 A549 cells or 3,000 NP9 cells, were done by triplicate on
96-well plates and 30,000 A549 or NP9 noninfected cells were
added, respectively. At day 7 for A549 cells and day 9 for
NP9 cells, the same protocol of total protein staining, quan-
tification, and statistical study as above was performed.
In this case, IC50 values were calculated as the number
of infected cells needed to produce 50% of culture growth
inhibition.
In vivo antitumoral efficacy
Animal studies were performed at the IDIBELL animal
facility (AAALAC unit 1155) and approved by the IDIBELL’s
Ethics Committee for Animal Experimentation. Sub-
cutaneous A549 or NP9 carcinoma tumors were established
by injection of 1.5 · 106 or 3 · 106 cells, respectively, into the
flanks of 6-week-old female Balb/C nu/nu mice (Harlan La-
boratories, Venray, B.V. Netherlands). To minimize the
number of animals used, each animal was implanted with
two tumors, one in each flank. When tumors reached
150 mm3 (experimental day 0; n = 8–10 tumors), mice were
randomized and were injected with a single intratumor in-
jection of PBS, 2 · 1010 vp of AAV6, 2 · 109 vp of ICOVIR15,
or 2 · 1010 vp of AAV6 and 2 · 109 vp of ICOVIR15 in a
volume of 20 ll in PBS. Tumor volume was defined by the
equation, V (mm3) = p/6 · W2 · L, where W and L are the
width and the length of the tumor, respectively. Data are
expressed as relative tumor size to the beginning of the
therapy. The statistical differences in relative tumor size be-
tween treatment groups were assessed by a two-tailed Stu-
dent’s unpaired t-test. For Kaplan–Meier survival curves, the
end point was established at ‡ 500 mm3. The survival curves
from the different treatments were compared. Animals
whose tumor size never achieved the threshold were in-
cluded as right-censored information. A log-rank test was
used to determine the statistical significance of the differ-
ences in time-to-event.
Results
Ad-AAV coinfection results in a large-plaque phenotype
We performed a cell-plaque assay to compare the plaque
phenotypes of cells infected with Ad alone or Ad and AAV.
We infected A549 cells with Ad5 or ICOVIR15 (Rojas et al.,
2010), each of them either alone or combined with AAV2 or
AAV6. Fifty cells from each infection condition were added
on top of near-confluent A549 monolayers and were covered
with agarose to force the viruses to spread from cell to cell.
Plaques derived from cells coinfected with Ad and either
AAV2 or AAV6 appeared earlier and had a larger size at any
given time point, for both Ad5 (Fig. 1a) and ICOVIR15 (Fig.
FIG. 1. Ad-AAV coinfection
enlarges plaque size. Cell
plaque assay of A549 cells in-
fected with (a) Ad5 or (b)
ICOVIR15 alone or combined
with either AAV2 or AAV6.
Fifty infected cells of each in-
fection condition were added
on top of A549 fresh mono-
layers previously seeded in
six-well plates. Cell plaques
were stained with MTT
and photographed at the in-
dicated time points. AAV,
adeno-associated viruses; Ad,
adenovirus.
374 LABORDA ET AL.
1b). Interestingly, cells coinfected with AAV6 developed
faster and larger plaques than AAV2; thus, we focused on
AAV6.
Coinfection with AAV6 enhances ICOVIR15 release
but decreases burst size
ICOVIR15 yield and release in the presence or absence of
AAV6 were quantified in three cell lines (Fig. 2). HEK293
(human embryonic kidney) are commonly used to propagate
Ads. A549 (lung adenocarcinoma) and NP9 (pancreatic ad-
enocarcinoma) are tumor cell lines commonly used as
models in virotherapy. Cells were synchronically infected
with ICOVIR15 alone or combined with AAV6. At the in-
dicated time points, SNs and CEs were harvested and Ad
was tittered using an antihexon staining-based method
(Cascallo et al., 2007). In HEK293 cells (Fig. 2a), AAV6 in-
creased ICOVIR15 release 10-, 15-, and 7-fold at 24, 48, and
72 hr postinfection, respectively ( p < 0.05), but decreased
1.87- and 2.17-fold ICOVIR15 total production at 48 and
72 hr postinfection, respectively ( p < 0.05). In A549 cells (Fig.
2b), coinfection with AAV6 increased ICOVIR15 release 87-,
34-, and 2.5-fold at 24, 48, and 72 hr postinfection, respec-
tively ( p < 0.05), but decreased total production 1.6-, 4.7-,
and 6.75-fold at 24, 48, and 72 hr postinfection, respectively
( p < 0.05). In NP9 cells (Fig. 2c), AAV6 enhanced ICOVIR15
release 13- and 5-fold compared with ICOVIR15 at 48
and 72 hr postinfection, respectively ( p < 0.05). Total pro-
duction was not affected in NP9 cells. A similar enhanced Ad
release and lower Ad production was observed when
infecting A549 cells with Ad5 and AAV6 (Supplementary
Fig. S1; Supplementary Data are available online at
FIG. 2. Ad-AAV coinfec-
tion enhances Ad release.
Viral production and release
kinetics of ICOVIR15 alone
or combined with AAV6 in
(a) HEK293, (b) A549, and (c)
NP9 cells. Extracellular (SN,
supernatant) and total (CE,
cell extract) Ad contents
were analyzed at the time
points indicated. Mean val-
ues (n = 3) – SD are plotted.
*p £ 0.05 by two-tailed un-
paired Student’s t-test com-
pared with ICOVIR15. (d)
Percentage of viral release
([virus released/virus pro-
duced] · 100) in A549 cells
infected with ICOVIR15 (50
MOI) alone or combined
with AAV6 (100, 1,000,
10,000, and 100,000 vp/cell)
at the indicated time points.
Each bar indicates the aver-
age of three samples (n = 3) –
SD. *p £ 0.05 compared with
ICOVIR15, #p £ 0.05 com-
pared with ICOVIR15/AAV6
(100), xp £ 0.05 compared with
ICOVIR15/AAV6 (10,000),
{p £ 0.05 compared with
ICOVIR15/AAV6 (100,000).
MOI, multiplicity of infection.
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www.liebertonline.com/hgtb). No differences of Ad content
in total CE at time point 0 were observed in any cell line
(Supplementary Fig. S2).
We extended the study on AAV6 effects on ICOVIR15
release and total production by coinfecting A549 cells with
different AAV6 doses. We measured the relative amounts of
Ad released (virus released/total virus produced) using four
AAV6 doses (100, 1,000, 10,000, and 100,000 vp/cell) to find
which dose enhanced ICOVIR15 release more efficiently (Fig.
2d). In all the time points analyzed, the dose of 1,000 vp/cell
induced the highest relative Ad release. This dose was also
the dose that induced the highest absolute amounts of virus
released (Supplementary Fig. S3).
The viability of ICOVIR15-infected cells is reduced
by AAV6
To detect morphology changes at early times associated to
AAV6 coinfection, A549 cells were infected with ICOVIR15
alone or ICOVIR15 and AAV6. As described (Timpe et al.,
2007), coinfected cells showed an apoptotic-like morphology
characterized by cell shrinkage and membrane blebbing as
soon as 36 hr postinfection (Fig. 3a). Cells infected with
ICOVIR15 alone showed minimal signs of cytopathic effect
at the same time point (36 hr), but complete cytopathic effect
at 72 hr postinfection. To further study this accelerated cell
death, we studied plasma membrane integrity and cell lysis
FIG. 3. AAV6 coinfection induces cell shrinkage, accelerates cell death, and enhances ICOVIR15 propagation in ICOVIR15-
infected cells. A549 cells were mock-infected or infected with ICOVIR15 (50 MOI) alone or combined with AAV6 (1,000 vp/
cell). (a) Cell morphology at the indicated hours postinfection. (b) Cell lysis measured by LDH release into the culture
medium. Mean values (n = 3) – SD are plotted. (c) Percentage of viable cells determined on the basis of exclusion of trypan
blue from the cell. Mean values (n = 3) – SD are plotted. #p £ 0.05 by two-tailed unpaired Student’s t-test compared with mock-
infected cells, *p £ 0.05 by two-tailed unpaired Student’s t-test compared with ICOVIR15-infected cells. (d) The IC50
(ICOVIR15 TU/cell needed to cause a reduction of 50% in cell culture viability) values obtained from comparative dose–
response curve of ICOVIR15 alone or combined with AAV6 (400, 4,000, 40,000, and 400,000 vp/cell) in A549 and NP9 cells.
At day 5–6 postinfection, plates were washed with PBS and stained for total protein content. Three different replicates were
quantified for each cell line. Mean – SD are showed. *p £ 0.05 by two-tailed unpaired Student’s t-test compared with
ICOVIR15. (e) The IC50 values (infected cells needed to cause a reduction of 50% in cell culture viability) obtained from
comparative dose–response curve of A549 or NP9 cells infected with ICOVIR15 alone or combined with AAV6 at day 7–8
after infection are shown. Three different replicates were quantified for each cell line. Mean – SD are shown. *p £ 0.05 by two-
tailed unpaired Student’s t-test compared with cells infected with ICOVIR15.
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using the same coinfection conditions. Cell lysis, measured
by LDH release, showed a marked increase ( p < 0.01) in co-
infected cells compared with ICOVIR15-alone infected cells
at early times (24 and 36 hr postinfection) (Fig. 3b). At later
times (48 and 72 hr postinfection), lysis was not significantly
different compared with ICOVIR15-infected cells. LDH levels
in noninfected cells remained basal during all the experi-
ment. Plasma membrane integrity and cell viability were
monitored by trypan blue exclusion (Fig. 3c). Loss of
membrane integrity and cell viability of coinfected cells ap-
peared as soon as 24 hr postinfection. A minority of cells
were viable 36 hr postcoinfection with ICOVIR15 and AAV6
(9.8%, 7.7%, and 1.7% of cells were viable at 36, 48, and 72 hr
postcoinfection, respectively). In contrast, the majority of
cells were viable at 36 and 48 hr postinfection with ICOVIR15
(95% and 85%, respectively). Viability was 11-fold higher for
ICOVIR15-alone infected cells compared with coinfected
cells (85.3% vs. 7.7%, p < 0.01) at 48 hr postinfection. Non-
infected cell viability remained near 100% during all the
experiment.
AAV6 enhances the ICOVIR15 propagation-mediated
cytotoxicity in vitro
Cell monolayers were infected with low doses of viruses
(achieved by serial dilutions) and incubated for several days
to allow multiple rounds of replication. Such propagation-
mediated cytotoxicity assays (IC50 assays; IC50, amount of
virus needed to reduce cell culture viability by 50%) were
performed by infecting preseeded monolayers of A549 or
NP9 cells with viruses or by seeding infected cells over them.
To prepare virus mixtures, four initial different doses of
AAV6 (400, 4,000, 40,000, and 400,000 vp/cell) and one ini-
tial dose of ICOVIR15 (200 transducing units [TU]/cell) were
used. The results showed that AAV6 enhanced dose de-
pendently the propagation-mediated cytotoxicity of ICOV-
IR15 (lower IC50 values) in both cell lines (Fig. 3d). Similar
results were obtained when seeding monolayers with serial
dilutions of cells infected with ICOVIR15 or ICOVIR15 and
AAV6. Coinfection strongly enhanced cytotoxicity in both
cells lines, decreasing dramatically the IC50 values (Fig. 3e).
Comparative dose–response curves from both assays are
shown in Supplementary Fig. S4.
ICOVIR15-AAV6 injection enhances antitumor activity
and prolongs mice survival after intratumor administration
Once we had demonstrated the ICOVIR15-AAV6-
enhanced cytotoxicity in vitro, we wanted to determine whether
it conferred a therapeutic advantage in vivo. Mice bearing
A549 or NP9 tumors were treated intratumorally with PBS,
AAV6 (2 · 1010 vp/tumor), ICOVIR15 (2 · 109 vp/tumor), or
a mixture of ICOVIR15 and AAV6 at these same doses in a
single injection (Fig. 4a). The AAV6 dose was 10-fold higher
than the dose of ICOVIR15 to increase tumor cell coinfection
probability. In the A549 model, coinjection reduced tumor
growth compared with PBS- and AAV6-injected groups from
day 14 postinjection (p.i.) ( p < 0.05) until day 38 of treatment,
when PBS and AAV6 groups had to be sacrificed because of
uncontrolled tumor growth. ICOVIR15 reduced tumor
growth compared with AAV6 at days 35 and 38 after treat-
ment ( p < 0.05). Coinjection reduced 2.6-fold the tumor
growth compared with ICOVIR15 injection at the end of
the experiment (day 66), although this difference was not
statistically significant. In the NP9 model, the combination
of both viruses resulted in a marked inhibition of tumor
growth. ICOVIR15-AAV6 coinjection decreased tumor
growth compared with control groups (PBS and AAV6) from
day 20 p.i. ( p < 0.05) and compared with ICOVIR15 from day
29 p.i. ( p < 0.05). At the end of the study (day 48 after
treatment), coinjection inhibited tumor growth 1.9-fold
compared with ICOVIR15. Kaplan–Meier analysis (Fig. 4b)
showed a survival benefit for the group treated with both
viruses compared with controls in A549 and NP9 models
( p < 0.05), and compared with ICOVIR15 group in NP9
model ( p < 0.05). ICOVIR15 treatment showed a trend to
improve the mean survival compared with control groups
(PBS and AAV6) in both models although did not achieve
statistical significance.
In summary, our results indicate that Ad coinfection with
AAV induces a large-plaque phenotype caused by an in-
crease in Ad release, which enhances Ad cytotoxicity in vitro
and antitumor efficacy in vivo.
Discussion
A clear phenotype associated to AAV contamination of
Ad stocks is the lower Ad production yield (Hoggan et al.,
1966; Carter et al., 1979; Timpe et al., 2006). As Ad, human
papiloma virus (HPV) can also function as an AAV helper,
and lower HPV yields have also been observed after AAV
coinfection. Intriguingly, it has been described that AAV
accelerates the HPV life cycle (Agrawal et al., 2002). Here we
describe that the combination of Ad5 or oncolytic Ad
ICOVIR15 with either AAV2 or AAV6 results in earlier and
larger-plaque phenotype. This phenotype is long-lived
(14 days postinfection; not shown), suggesting an improve-
ment in propagation that is sustained during multiple rep-
lication rounds. As a large-plaque phenotype correlates with
enhanced antitumor activity of oncolytic Ads, we attempted
to elucidate if the AAV-induced large-plaque phenotype
could be applied to virotherapy. AAV2 has been largely used
as a reference serotype for AAV, but we also included AAV6
in our analysis to extend the observations to another AAV
serotype. Compared with AAV2, AAV6 produced even fas-
ter and larger Ad plaques. AAV6’s high capability for airway
epithelia transduction is well documented; however, the in-
fectivity of AAV6 in A549 lung adenocarcinoma cells is not
superior to AAV2 (Grimm et al., 2008), suggesting that such
tropism for lung is not the cause for the AAV6 larger-plaque
phenotype. Hence, we focused on serotype 6 for oncolytic
studies.
Ad large-plaque phenotype has been associated to en-
hanced progeny release (Sauthoff et al., 2000; Doronin et al.,
2003; Gros et al., 2008). Accordingly, AAV6 enhanced
ICOVIR15 release in all cell lines analyzed. However, the
time after infection when we detected the highest difference
on Ad release induced by AAV was different for each cell
line. NP9 showed a delay in this AAV-induced Ad release
that could be associated to a lower permissiveness to Ad
replication (lower production yields) than A549 and HEK293
cells. In HEK293 and A549 cells, AAV6 decreased Ad pro-
duction as expected (Carter et al., 1979; Timpe et al., 2006).
Moreover, this phenotype was not restricted to an oncolytic
Ad, as AAV6 also enhanced Ad5 release. The amount of Ad
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present in the total CE immediately after the coincubation
time (time point 0) was not influenced by the presence of
AAV (Supplementary Fig. S2), suggesting that the AAV’s
effect on Ad is not associated to initial virus entry.
As Ad is affected by AAV in a dose-dependent manner
(Timpe et al., 2006), a range of coinfection conditions with
AAV6 were used to evaluate the effects on ICOVIR15 release
and total production in A549 cells. Compared with other
doses, the dose of 1,000 vp/cell resulted in the highest ratio
of released virus to total produced virus and, importantly, in
the highest absolute amount of virus in the SN with complete
virus release after 48 hr postinfection. Hence, looking only at
Ad presence in the SN, the enhanced release overcomes the
lower production. We did not find a dose-dependent corre-
lation, as lower or higher doses than 1,000 vp/cell had less
impact on virus release.
Several strategies to enhance Ad release have been de-
scribed: ADP overexpression (Doronin et al., 2003), apoptosis
induction by deletion of genes such as E1B19K (Sauthoff
et al., 2000) or insertion of proapoptotic transgenes (Sauthoff
et al., 2002), and bioselection of mutagenized Ads (Sub-
ramanian et al., 2006; Gros et al., 2008). ADP overexpression
and apoptosis induction accelerate cell death (Sauthoff et al.,
2000; Doronin et al., 2003; Subramanian et al., 2006). It has
also been observed that AAV induces a characteristic apo-
ptotic cell morphology on Ad-infected cells, with cell
shrinkage and membrane blebbing (Timpe et al., 2007). We
observed this apoptotic-like morphology (Fig. 3a) as soon as
36 hr after coinfecting with AAV6 at 1,000 vp/cell. This
AAV-induced apoptotic-like phenotype correlated to accel-
erated cell death and cell membrane disruption, which were
measured by LDH secretion and trypan blue exclusion. This
enhanced cytotoxicity correlates with previous reports of
increased cytolysis and apoptosis during the first 3 days after
infection of A549 cells with Ad5 and AAV2 (Timpe et al.,
2007). However, Jing et al. (2001) saw opposite results in
HeLa cells that could be related to the different cells used.
Our results in A549 and NP9 cells support those of Timpe
et al. 2007 in favor of an AAV-induced cytotoxicity.
The mechanism whereby AAV increases Ad cytotoxicity is
not clear. Here we describe an enhanced release with prema-
ture cell death and a characteristic apoptotic-like morphology.
Previous reports indicate that AAV Rep proteins induce ap-
optosis (Zhou and Trempe, 1999; Zhou et al., 1999; Schmidt
et al., 2000; Timpe et al., 2007) and that AAV Rep protein
expression is inhibited at high AAV doses (Carter et al., 1979;
Timpe et al., 2006), decreasing theoretically the proapoptotic
effects. In the other hand, adenoviral E1B19K and ADP pro-
teins are related with viral spread, apoptosis, and cytopathic
effect (Tollefson et al., 1996a; Subramanian et al., 2006).
FIG. 4. AAV6 enhances ICOVIR15 antitumor efficacy and prolongs mice survival in two carcinoma tumor xenografts. A549
and NP9 tumor xenografts were treated with a single intratumor dose of PBS, AAV6 (2 · 1010 vp/tumor), ICOVIR15 (2 · 109
vp/tumor), or a mixture of ICOVIR15 and AAV6 at the same doses. (a) Relative tumor growth (percentages of size at
treatment, mean – SE) of 8–10 tumors/group is plotted. *p £ 0.05 by two-tailed unpaired Student’s t-test compared with PBS,
#p £ 0.05 by two-tailed unpaired Student’s t-test compared with AAV6, xp £ 0.05 by two-tailed unpaired Student’s t-test
compared with ICOVIR15. (b) Kaplan–Meier survival curves. The end point was established at a tumor volume of ‡ 500 mm3.
*p £ 0.05 by long-rank test compared with mice injected with PBS, #p £ 0.05 by long-rank test compared with mice injected with
AAV6, xp £ 0.05 by long-rank test compared with mice injected with ICOVIR15. PBS, phosphate buffered saline.
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From a virotherapy perspective, our aim was to enhance
cell lysis, Ad propagation, and antitumor activity of onco-
lytic Ads. As AAV induced a faster Ad release and increased
cytotoxicity, but reduced virus production (burst size), we
examined how AAV6 affected ICOVIR15 propagation. With
this purpose, propagation-mediated cytotoxicity assays were
performed in A549 and NP9 cells using serial virus dilutions
(IC50 assays). ICOVIR15 propagated faster in the presence of
AAV6 at all doses tested. Earlier progeny release is the most
obvious explanation for this rapid propagation, increasing
the speed of cell-to-cell spread. Using serial dilutions of in-
fected cells, we also observed a significant IC50 reduction (11-
fold) in both cell lines. The use of coinfected cells is of interest
as oncolytic viruses have been administered by carrier cells
(Willmon et al., 2009). Our results indicate that the lower Ad
yields associated to AAV coinfection are compensated by an
earlier release of virus to the SN, and the final outcome is a
faster Ad propagation and cytotoxicity (lower IC50 values).
To apply our findings to virotherapy, we treated lung and
pancreatic adenocarcinomas with a mixture of AAV and
oncolytic Ad. It is reported that AAV per se can function as a
tumor suppressor (Khleif et al., 1991); thus, an AAV-alone
treatment was also included. Coinjection with AAV6 im-
proved the antitumor efficacy of ICOVIR15. The faster Ad
release and the lower Ad total production, both induced by
AAV coinfection, may pose a challenge when attempting to
correlate efficacy with intratumoral virus amount by Ad
DNA quantification or capsid staining. In fact, we did not
find significant differences between intratumor Ad ge-
nomes of ICOVIR15/AAV6 and ICOVIR15 groups (data not
shown). The strategy to use AAV to foster Ad oncolysis re-
quires coinfection of tumor cells; to maximize it, we used
intratumoral administration of a mixture of viruses. Despite
that this administration route is commonly used in vir-
otherapy, ideally, systemic administration would be pre-
ferred for metastatic cancer. Systemic administration of
both viruses would require an AAV biodistribution study in
animals bearing tumors after intravenous administration.
However, given the limited tumor-targeting capability of
Ad, the probability of coinfection of target cells is likely low.
Therefore, novel approximations that allow Ad and AAV
codelivery should be explored. Use of carrier cells would be
an option (Coukos et al., 1999; Garcia-Castro et al., 2005;
Hamada et al., 2007). Another strategy could use nonviral
vectors carrying infectious plasmids encoding both viruses
(Kwon et al., 2011). This strategy is feasible as AAV plasmids
are infectious when transfected and plasmids with self-
excising Ad genomes have been developed (Stanton et al.,
2008).
Our results point that contamination of Ad stocks with
AAV could result in enhanced oncolysis, contrary to what
could be expected considering only the widely accepted
lower Ad yields. Besides the implication that intentional
mixing of Ad and AAV may have for efficacy, this obser-
vation also raises a caution note on oncolytic Ad potency
comparisons, particularly by direct intratumoral adminis-
tration, as it would require prior AAV detection.
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Pittsburgh Cancer Institute, Pittsburg, PA) and Miriam Ba-
zan-Peregrino (Institut d’Investigacions Biomèdiques de
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